PMID: 6104840Jan 1, 1980

Residual effects of hypnotics: triazolam, flurazepam, and nitrazepam

Psychopharmacology
C OguraW M Wardell

Abstract

The residual effects of three hypnotics were investigated by the method of 24-h polygraphy (EEG, EMG, and EOG). The drugs were triazolam 0.25 mg and 0.5 mg, flurazepam 15 mg and 30 mg, nitrazepam 5 mg and 10 mg, and placebo. The subjects were healthy volunteers, eight men and eight women with an average age of 34.3 years. The number of total polygraphic records was 77. Triazolam 0.25 mg and 0.5 mg, flurazepam 30 mg, and nitrazepam 10 mg showed definited sleep inducing and sleep maintenance effects in night recordings. Flurazepam 15 mg and 30 mg and nitrazepam 5 mg and 10 mg were followed by residual effects in morning, afternoon and evening recording periods on the day after the administrations of the hypnotics. However, no effects were seen on the day after the administration of triazolam 0.25 mg and 0.5 mg except for some slight residual effects in the morning. Thus triazolam 0.25 mg and 0.5 mg produces less residual effect than do flurazepam 15 mg and 30 mg, and nitrazepam 5 mg and 10 mg, and 24-h polygraphy is useful for measuring the residual effects of hypnotics.

References

Jan 1, 1975·Psychopharmacologia·G VogelK Sexton
Sep 11, 1975·Clinical Pharmacology and Therapeutics·K RickelsA Schilling
Sep 28, 1973·Psychopharmacologia·A J Bond, M H Lader
Feb 26, 1971·Nature·A J Walters, M H Lader

Citations

Oct 31, 2002·Human Psychopharmacology·Alain PatatIan Hindmarch
Jan 1, 1982·Psychopharmacology·C L Spinweber, L C Johnson
Jan 1, 1983·Psychopharmacology·C Gorenstein, V Gentil
Jul 1, 1996·Psychopharmacology·L Parrino, M G Terzano
Jun 1, 1993·Aging : Clinical and Experimental Research·M SeppäläL Sourander
Mar 1, 1984·Electroencephalography and Clinical Neurophysiology·G D Novack, K M Owenburg
Sep 1, 1987·Journal of Affective Disorders·J Ananth
Sep 1, 1987·Journal of Affective Disorders·D V Sheehan
Jan 1, 1983·Progress in Neuro-psychopharmacology & Biological Psychiatry·Y D Lapierre
May 1, 1995·Progress in Neuro-psychopharmacology & Biological Psychiatry·Y MizukiM Yamada
Jun 6, 2002·Psychiatry and Clinical Neurosciences·H YamaderaShunkichi Endo
Aug 11, 1983·The New England Journal of Medicine·D J GreenblattD R Abernethy
Jun 13, 1991·The New England Journal of Medicine·D J GreenblattR I Shader
Jan 1, 1990·Journal of Psychoactive Drugs·V L Martin
Oct 1, 1985·British Journal of Clinical Pharmacology·G TedeschiA Richens
Jan 1, 1986·Acta Psychiatrica Scandinavica. Supplementum·A N GriffithsA Richens
Jul 1, 1982·Journal of Clinical Pharmacology·T RoehrsT Roth
Jan 18, 2003·Sleep Medicine Reviews·Shawn D Youngstedt
Sep 25, 2003·Sleep Medicine Reviews·Shawn D Youngstedt
Jan 1, 1997·Annual Review of Entomology·D YamamotoA Komatsu
Jan 1, 1984·The Journal of International Medical Research·C J McAlpineC S Elliott
Jul 1, 1983·Drug Intelligence & Clinical Pharmacy·P D Kroboth, R P Juhl
Sep 17, 1987·The New England Journal of Medicine·D J GreenblattR I Shader
May 1, 1983·Pharmacotherapy·T RothF Zorick

Related Concepts

Electroencephalogram
Surface Electromyography
Electrooculograms
Staurodorm
Imeson
Sleep, Slow-Wave
Anti-Anxiety Effect
Trilam

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells. It also follows CRISPR-Cas9 approaches to generating genetic mutants as a means of understanding the effect of genetics on phenotype.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Pediculosis pubis

Pediculosis pubis is a disease caused by a parasitic insect known as Pthirus pubis, which infests human pubic hair, as well as other areas with hair including eye lashes. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Rh Isoimmunization

Rh isoimmunization is a potentially preventable condition that occasionally is associated with significant perinatal morbidity or mortality. Discover the latest research on Rh Isoimmunization here.

Pharmacology of Proteinopathies

This feed focuses on the pharmacology of proteinopathies - diseases in which proteins abnormally aggregate (i.e. Alzheimer’s, Parkinson’s, etc.). Discover the latest research in this field with this feed.

Enzyme Evolution

This feed focuses on molecular models of enzyme evolution and new approaches (such as adaptive laboratory evolution) to metabolic engineering of microorganisms. Here is the latest research.

Alignment-free Sequence Analysis Tools

Alignment-free sequence analyses have been applied to problems ranging from whole-genome phylogeny to the classification of protein families, identification of horizontally transferred genes, and detection of recombined sequences. Here is the latest research.